(323) Advancing the management of multiple myeloma via multiphase initiative centered on regional payer-provider forums

Background: : Multiple myeloma (MM) is a key cost driver in oncology, owing to disease progression and the overall chronicity of the condition. Treatment requires a nuanced approach using several different classes of drugs, with chimeric antigen receptor T-cell and bispecific antibody therapies representing the latest additions.

Objective: : To identify regional trends in managing MM, barriers to optimal treatment, best practices in patient care, and opportunities for collaboration via an open forum among regional clinical specialists and managed care decision makers.

Methods: : Two virtual roundtables were held in the Southwest and Northeast regions in November 2024 among managed care professionals (n=8), oncology specialist providers (n=4), and one patient advocacy representative. Participants heard testimony from patients with MM and reviewed relevant clinical information prior to engaging in moderated discussions. The findings were shared via webcast as part of a larger initiative to disseminate continuing education for managed care professionals.

Results: : Regional trends in the Southwest included the challenges associated with geography and transportation to tertiary treatment centers for specialized MM care, which are exacerbated by social determinants of health (SDOH). A push for increased adoption of bispecific antibodies in the community oncology setting with oversight by tertiary care centers and non-punitive integration of clinical pathways were identified as best practices. In the Northeast, drug shortages and high costs associated with generic alternatives were cited as key challenges. Participants noted coordination among community oncology providers and tertiary care centers as a key best practice, in addition to provider alignment with evidence-based treatment protocols. Opportunities for collaboration across both regions included consultation with oncology specialists on coverage policies as a cost management strategy. Participants also suggested an organized means to coordinate care between community oncology practices and centers of excellence to facilitate the utilization of newer targeted therapies.

Conclusions: : Increased coordination between payers and providers has the potential to improve patient access to newer targeted therapies for MM regardless of geography and/or SDOH. Future efforts will include additional roundtable meetings with payers and oncology specialist providers in other regions to advance collaboration.

Sponsorship:: Regeneron Pharmaceuticals, Inc.